Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 5
2009 12
2010 7
2011 13
2012 21
2013 16
2014 15
2015 22
2016 17
2017 18
2018 13
2019 14
2020 20
2021 21
2022 33
2023 21
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M; ZeNix Trial Team. Conradie F, et al. N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430. N Engl J Med. 2022. PMID: 36053506 Free PMC article. Clinical Trial.
BACKGROUND: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. The appropriate dose o …
BACKGROUND: The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resista …
Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China.
Zhang P, Tan J, Lin Y, Zhang H, Deng G, Chen X. Zhang P, et al. Drug Discov Ther. 2022 May 17;16(2):96-98. doi: 10.5582/ddt.2022.01024. Epub 2022 Apr 20. Drug Discov Ther. 2022. PMID: 35444071 Free article.
Linezolid has been one of the key anti-tuberculosis agents for the treatment of multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). ...Many scholars in China have reported their …
Linezolid has been one of the key anti-tuberculosis agents for the treatment of multidrug-resistant tuberculo …
Linezolid for Drug-Resistant Tuberculosis.
Thwaites G, Nguyen NV. Thwaites G, et al. N Engl J Med. 2022 Sep 1;387(9):842-843. doi: 10.1056/NEJMe2208554. N Engl J Med. 2022. PMID: 36053511 No abstract available.
Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Seaworth BJ, Griffith DE. Seaworth BJ, et al. Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TNMI7-0042-2017. Microbiol Spectr. 2017. PMID: 28361737 Free article. Review.
The global epidemic of multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampin was recently reported as larger than previously estimated, with at least 580,000 new cases …
The global epidemic of multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis strains …
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M; Nix-TB Trial Team. Conradie F, et al. N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814. N Engl J Med. 2020. PMID: 32130813 Free PMC article. Clinical Trial.
BACKGROUND: Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. ...We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively …
BACKGROUND: Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically h …
Drug resistant TB - latest developments in epidemiology, diagnostics and management.
Tiberi S, Utjesanovic N, Galvin J, Centis R, D'Ambrosio L, van den Boom M, Zumla A, Migliori GB. Tiberi S, et al. Int J Infect Dis. 2022 Nov;124 Suppl 1:S20-S25. doi: 10.1016/j.ijid.2022.03.026. Epub 2022 Mar 25. Int J Infect Dis. 2022. PMID: 35342000 Free article. Review.
AIM: The aim of this review is to inform the reader on the latest developments in epidemiology, diagnostics and management. EPIDEMIOLOGY: Drug-resistant Tuberculosis (DR-TB) continues to be a current global health threat, and is defined by higher morbidity an …
AIM: The aim of this review is to inform the reader on the latest developments in epidemiology, diagnostics and management. EPIDEMIOLOGY: …
Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
Yang M, Zhan S, Fu L, Wang Y, Zhang P, Deng G. Yang M, et al. Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12. Drug Discov Ther. 2022. PMID: 35418550 Free article.
Tuberculosis has become a great global public health threat. Compared with drug-susceptible tuberculosis (TB), the treatment regimens for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tub …
Tuberculosis has become a great global public health threat. Compared with drug-susceptible tuberculosis (TB), the trea …
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Diriba G, Alemu A, Yenew B, Tola HH, Gamtesa DF, Mollalign H, Eshetu K, Moga S, Abdella S, Tollera G, Kebede A, Dangisso MH. Diriba G, et al. Int J Infect Dis. 2023 Jul;132:50-63. doi: 10.1016/j.ijid.2023.04.392. Epub 2023 Apr 16. Int J Infect Dis. 2023. PMID: 37072053 Free PMC article.
OBJECTIVES: To estimate the pooled proportion of extensively drug-resistant tuberculosis (XDR-TB) and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) in patients with multidrug-resistant TB (MDR-TB). . …
OBJECTIVES: To estimate the pooled proportion of extensively drug-resistant tuberculosis (XDR-TB) and pre-ext …
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB. Silva DR, et al. J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. J Bras Pneumol. 2018. PMID: 29791557 Free PMC article. Review.
Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. ...The objective of this review was to summarize what has be …
Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) …
Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria.
Oehadian A, Santoso P, Menzies D, Ruslami R. Oehadian A, et al. Tuberc Respir Dis (Seoul). 2022 Apr;85(2):111-121. doi: 10.4046/trd.2021.0122. Epub 2022 Jan 20. Tuberc Respir Dis (Seoul). 2022. PMID: 35045688 Free PMC article. Review.
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and isoniazid. Extensively drug-resistant TB, a rare type of MDR-TB, is caused by an organism that is resistant to quino …
Multidrug-resistant tuberculosis (MDR-TB) is caused by an organism that is resistant to both rifampicin and ison …
242 results